Compare Badger Meter Inc (BMI) vs Novartis AG (NVS) Price & Performance

Badger Meter (BMI) trades at $138.86, up 1.23% today, with a bullish technical signal from moving averages and a consensus analyst price target of $155.20. Recent earnings show a Q2 2026 beat but misses in prior quarters, while financials indicate solid profitability with a 14.27% net income margin. The stock faces headwinds from multiple class-action lawsuits alleging securities fraud, as reported by Business Wire and GlobeNewsWire in early August 2026, though insider buying by a VP in late July signals confidence.

The outlook is mixed: strong fundamentals and analyst upside support growth, but legal risks and earnings volatility pose challenges. Investors may find value if legal concerns resolve, but caution is warranted due to potential sentiment pressure from ongoing litigation.

Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.

The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.